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Abstract
The aim of our study was to trace the dynamic changes of hospital-associated methicillin-resistant
Staphylococcus aureus (HA-MRSA) lineages in Italy, comparing the genotypic backgrounds of
contemporary isolates over a period of 17 years, with those of a sample of early MRSA strains from
1980.
In total, 301 non-repetitive MRSA clinical isolates, recovered from 19 Italian hospitals between
1990 and 2007 were selected and analyzed for their antibiotic resistance, typed by PFGE and
SCCmec, grouped into clonal-types and further characterized using Multi Locus Sequence Typing
(MLST). A sample of fifteen early MRSA strains from 1980 was also used for comparison.
The most interesting feature was the recent increase of ST228-MRSA-I (formerly the Italian clone;
PFGE E) over the period 2000–2007 (57%), when compared to the period 1990–1999 (29%), and
its stability to date, associated with a decrease of the highly epidemic ST247-MRSA-IA (formerly
the Iberian clone; PFGE A), (23% from 1990 to 1999, 6% from 2000 to 2007). ST1-MRSA-I (1 out
of 2 strains carrying ccrA2B2), ST8-MRSA-I (4 strains), ST15-MRSA-I (1 out of 4 carrying ccrA2B2)
and ST30-MRSA-I (2 out of 5 carrying no ccrAB-types and ccrC) were the predominant earliest STs
among the MRSA strains in 1980.
A temporal shift in the susceptibility levels to glycopeptides was observed: strains with vancomycin
MIC of ≥ 2 mg/L increased from 19.4% to 35.5%.
In conclusion, we describe the alternation of MRSA clones that occurred in hospitals from 1990 to
2007 and the increase of the glycopeptide MIC levels, reflecting a worldwide trend. We document
the detection of ST1, ST8, ST15 and ST30 in the 1980 isolates; we hypothesize their possible
latency and their appearance as the current CA-MRSA clones.
Introduction
Among EU countries, Italy, together with Spain, Greece,
Portugal, and Great Britain, has a high frequency of isola-
tion of methicillin-resistant Staphylococcus aureus (MRSA)
in hospitals. After an initial and continuous increase
between 1994 and 2001 [1], the annual reports from
EARSS (1999–2007) described the isolation of MRSA
from bloodstream infections in 1999 as 40%, but, unlike
the trend in other European countries such as Great Brit-
ain or Greece, a constant small average decrement was reg-
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istered in the 2001–2007 period, reaching an average
value of 33.7% in 2007 http://www.earss.rivm.nl.
These data are only partially representative of the Italian
nosocomial MRSA prevalence. MRSA is responsible for
various infections and considerable variations between
institutions and wards, often in the same geographical
areas, exist, demonstrating that MRSA prevalence, in some
settings, significantly exceeds previous estimates [1],
sometimes accounting for approximately 40–60% of all
hospital acquired strains [2-5]. There could be many
explanations for these differences: infection control meas-
ures, antibiotic prophylaxis and treatments used in each
ward/hospital and, not less important, the clonal and
often epidemic nature of these microrganisms. Certain
strains can be found worldwide yet only few clones are
responsible for most MRSA infections [1,6,7].
Analysis of more than 3,000 isolates from Southern Europe,
the United States, and South America, showed that nearly
70% of them belonged to five major pandemic clones,
namely the Iberian (ST 247-MRSA-IA), Brazilian (ST239-
MRSA-IIIA), Hungarian (ST239-MRSA-III), New York/Japan
(ST5-MRSA-II), and Pediatric (ST5-MRSA-IV) clones [8].
Dominant and minor lineages constitute the S.aureus popu-
lation [9]. Each lineage is remarkably distinct and isolates of
the same lineage, but from diverse geographical locations or
from different periods, can be remarkably similar (except for
their mobile genetic element – MGE – contents that account
for 10–20% of the S.aureus chromosome) [10,11]. Evolu-
tion of lineages happened independently by different mech-
anisms [12] and MGEs encoding virulence and resistance
genes can move into and out of strains.
In recent years, the widespread use of antibiotics has
undoubtedly accelerated the evolution of S.aureus, and
led to the emergence of strains that have systematically
acquired multiple resistance genes [1,13]. With the cur-
rent emergence of multi-drug resistant isolates in hospi-
tals on the one hand [14] and the dramatically increased
incidence of hyper-virulent community-associated MRSA
(CA-MRSA) on the other [15,16], MRSA has been able to
evolve rapidly and create new clinical problems.
A greater understanding of how the bacteria have evolved
in any geographical area can help us to rapidly identify
new outbreak strains and even prevent emergence and dif-
fusion of more resistant clones [17].
There have been only few studies reporting the dynamics
of MRSA over long periods of time [18-23]. In almost all
these studies, despite the worldwide predominance of a
few MRSA clones, the authors demonstrated local strain
diversity and reported that predominant MRSA strains
seemed to change over time and emerging clones were
appearing or replacing the oldest.
The aim of our study was to trace the dynamics of geno-
typic changes and the shifts in the levels of susceptibility
to antibiotics, including glycopeptides, of MRSA lineages
in Italy, comparing the genotypic backgrounds of contem-
porary isolates with those of a sample of early MRSA
strains from 1980. The study also provides a complete
overview of predominant and sporadic MRSA strains in
our country, over a period of 17 years, from two surveil-
lances projects (1990–1998 and 2000 – 2007).
Methods
Isolates
Three hundred and one MRSA clinical isolates, recovered
from 19 Italian hospitals between 1990 and 2007 were
selected from two Staphylococcus aureus collections, which
were sent to our laboratory during previous multi-centre
studies. The first collection (called A throughout the text) of
160 strains was selected as non-repetitive isolates represent-
ative of the different parts of Italy from among 426 methi-
cillin-resistant  S.aureus  (MRSA) strains isolated in the
period 1990–1999 [24]. The second group of 141 strains
(called B), were isolated in the period 2000–2007, and
were selected with the same criteria described above, from
among approximately 1,000 different S.aureus isolates [25].
Both groups of isolates were from various clinical speci-
mens and in particular, group A: 37% of cases from lower
respiratory tract specimens, 29% from blood cultures (7%
associated to a CVC), 1% from cerebrospinal fluid, and
31% from SSSIs. Group B isolates were almost compara-
ble, with a greater percentage only for lower respiratory
tract specimens (53%), 19% from blood cultures, 3%
from cerebrospinal fluid and 25% from SSSIs.
A sample of fifteen early MRSA strains from 1980 was
used for comparison [26].
All isolates were re-identified at the species level by cata-
lase test, S. aureus agglutination test (STAPHYLASE TEST;
Oxoid Ltd. Basingstoke, Hampshire, UK) and biochemi-
cal tests (API-Staph system; bio Mérieux SA, Marcy-
l'Etoile, France). All strains were stored at -80°C until use.
Methicillin-resistance was evaluated by disk diffusion
method, and correlated to the presence of the mecA gene
(see below).
The distribution of strains throughout Italy was, in both
projects, approximately 20% from hospitals in Northern
Italy, 35% from the center, and 45% from Southern Italy.
In vitro susceptibility testing of antibiotics
The antimicrobial susceptibility profiles of the 301 MRSA
strains to the main classes of antibiotics were determined
by using the Kirby-Bauer method, according to CLSI
guidelines [27]. The MRSA isolates were tested against a
panel of 9 antimicrobial agents as follows: oxacillin-1 μg,Annals of Clinical Microbiology and Antimicrobials 2009, 8:22 http://www.ann-clinmicrob.com/content/8/1/22
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ciprofloxacin-5 μg, chloramphenicol-30 μg, gentamicin-
10 μg, erythromycin-15 μg, clindamycin-2 μg, trimetho-
prim-sulfamethoxazole-25 μg, rifampin-5 μg and tetracy-
cline-30 μg.
In vitro susceptibility testing for vancomycin, teicoplanin,
quinupristin/dalfopristin, linezolid, tigecycline and dap-
tomycin was further performed by the broth microdilu-
tion method to determine the minimum inhibitory
concentrations (MICs), following the CLSI guidelines
[27]. All antibiotics were kindly provided, as standard ref-
erence powders, by the following manufacturers: dapto-
mycin from Novartis (Basel, CH); linezolid from Pfizer
(Groton, CT, USA); quinupristin/dalfopristin and teico-
planin from Aventis (West Malling, UK). Vancomycin was
from Sigma Chemical (St. Louis, MO, USA).
MICs were determined using Muller-Hinton broth
(Oxoid, Milan, Italy), and for daptomycin tests the broth
was supplemented to yield a final concentration of 50 mg/
L calcium. S. aureus ATCC 29213 was used as quality con-
trol. Results were read after incubation at 37°C for 18–24
h. Susceptibility to daptomycin was defined as a MIC
value of ≤ 1 mg/L; CLSI guideline MIC breakpoints were
used for all the other antibiotics tested [27].
Pulsed-field gel electrophoresis (PFGE)
Genomic DNA was prepared in agarose plugs as previ-
ously described [28]. DNA was digested with 20 U of SmaI
(BioLabs, New England, USA) at 30°C overnight. PFGE
was carried out in a CHEF-DR II apparatus; (Bio-Rad, CA,
USA). Macrorestriction fragments were separated on 1%
(wt/vol) ultra pure agarose gels (Sigma Aldrich, S.Louis,
MO, USA) at 6 V/cm for 21 h at 14°C, with pulse times of
5 s – 35 s, to separate SmaI patterns. Lambda DNA con-
catemers (New England BioLabs, Beverly, MA, USA) were
used as molecular size markers.
Similarities among macrorestriction patterns were previ-
ously identified according to established criteria [29] in
each of the three time frames. The comparison of similar-
ities among groups for a long-term evaluation was per-
formed by using the type strain of each PFGE profile of
each time frame as internal standard.
PCR and SCCmec typing
Genomic DNA was extracted from all bacterial cultures and
used as a template for amplification. All isolates were
screened for the presence of the mecA gene. PCR experiments
were carried out following procedures previously published
[28]. PCR products were analyzed by electrophoresis on 1%
agarose gels (Sigma Aldrich, Saint Louis Mo, USA).
The amplification procedure for the detection of the Pan-
ton-Valentine Leukocidin (PVL) was performed as previ-
ously published [16].
The SCCmec cassettes were first determined by a multi-
plex-PCR protocol previously described, and assigned to
the corresponding types [30]. Furthermore, the results
were confirmed by different multiplex-PCR protocols,
focusing on the mec gene complex and the ccr gene com-
plex [31].
Molecular typing
All strains were grouped into clonal groups on the bases
of their antibiotype, PFGE profile and SCCmec type, and
representative isolates of the main PFGE sub-types A, B
and E were further characterized by Multi Locus Sequence
Typing (MLST), while all the other strains belonging to
PFGE C, G, sporadic clones and 1980 strains were
sequenced.
The clones were typed following the current nomencla-
ture (ST-MRSA-SCCmec), except in those contexts in
which maintaining the old nomenclature is necessary to
understand the diversity existing in each MLST profile.
The sequences of the seven housekeeping genes used for
MLST, corresponding to the allelic profile arcC-aroE-glp-
gmk-pta-tpi-yqiL, were obtained by comparing the
sequences obtained with those in the MLST database
http://mlst.zoo.ox.ac.uk[32]. All STs described in the
study were deposited on the MLST website and were com-
pared with the major international S. aureus STs pub-
lished.
Statistical analysis
Glycopeptide MIC trends over the 17 years were assessed
using non-parametric methods. Chi-square and Fisher's
exact tests were performed and significance was defined as
P < 0.001.
Results
Description of MRSA clones
The majority of MRSA clones in Italy, in agreement with
the results of a previous study on strains isolated in 1990,
belonged to six major clones: ST8-MRSA-I, ST247-MRSA-
IA, ST239-MRSA-IIIA, ST228-MRSA-I, ST247-MRSA-I/IA
and ST22-MRSA-IV and several minor clones. All these
strains were previously typed by PFGE analysis (together
with  ClaI/mecA and ClaI/Tn554  and SCCmec), and
grouped in six MRSA clones previously known as Archaic
and Iberian (PFGE profile A, including, in both periods of
time, 32 closely related sub-types), Brazilian (PFGE pro-
file B, with 6 sub-types), Italian (PFGE profile E, with 10
sub-types), Rome (PFGE profile C) and Gentamicin-Sus-
ceptible (PFGE profile G).
Figure 1a shows the distribution of the MRSA clones in the
A and B periods covering seventeen years. The beginning
of the 1990s was characterized by the presence (16% of
isolates) of ST8, carrying the SCCmec type I. In 1993–Annals of Clinical Microbiology and Antimicrobials 2009, 8:22 http://www.ann-clinmicrob.com/content/8/1/22
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1995, one major international epidemic clone, ST247-
MRSA-IA, appeared in our hospitals (23%), together with
ST228-MRSA-I circulating in our country (29%).
Another international clone, ST239-MRSA-IIIA, found to
be resistant to cotrimoxazole, appeared in our hospitals
around 1994 (9%), together with the local clone ST247-
MRSA-I/IA, showing different phenotypic and genotypic
features (erythromycin and clindamycin susceptibility;
PFGE C), named Rome clone to differentiate it from the
Iberian one. It appeared at the same time as ST239-MRSA-
IIIA, but it has only been detected sporadically to date.
In 2000, we saw the decrease of ST247-IA (6% of isolates),
the increase of ST228-I (57%), but also the re-appearance
of ST8 (UK EMRSA-2/-6) carrying the SCCmecIV (7% of
strains) instead of the SCCmecI, characteristic of the
period between 1985–1990 (data not shown). Besides the
Description of MRSA clones Figure 1
Description of MRSA clones. a) Distribution of the MRSA clones in periods A (1990–1999) and B (2000–2007); b) Descrip-
tion of the molecular backgrounds (ST, SCCmec and CC) of main clones isolated in Italy, correlated to their previous names; c) 
Graphical representation of alternation of MRSA clones in Italy during the 27-year period of study. *Italian and Southern Ger-
many clones belong to the same ST228-MRSA-I, but they differ for their PFGE profile. **UK EMRSA-15 was often reported in 
literature as gentamicin-susceptible MRSA (GS-MRSA) clone. (ST: Sequence-Type; SCCmec: Staphylococcal Cassette Chromo-
some mec; CC: Clonal-Complex).
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major international clones, the isolation of a gentamicin-
susceptible one, ST22-MRSA-IV, was detected in some
hospitals, reaching 14% of isolates.
The lukF-PV and lukS-PV genes were detected in three CA-
MRSA strains, belonging to ST8 and ST30, carrying SCC-
mec IV, and ST88, carrying SCCmec V.
The original and current nomenclature and molecular
characteristics of each clone are shown in Figure 1b.
The group of strains isolated in 1980 was included for com-
parison (15 strains); ST8-MRSA-I (4 strains), remaining 11
strains belonged to ST1-MRSA-I (2 strains), ST15-MRSA-I
(4 strains) and ST30-MRSA-I (5 strains), while of these 11
only 4 strains carried a variant of SCCmec type I. In particu-
lar those belonging to ST1-MRSA-Ilike (1 strain) and ST15-
MRSA-Ilike (1 strain) carried ccrA2B2 recombinases instead
of ccrA1B1, while ST30-MRSA-Ilike (2 strains) did not carry
any recombinases genes (figure 1c). SCCmec multiplex PCR
assays did not show any difference between the common
type I (pls, mecA and dcs loci) and the variant. Recombi-
nases multiplex PCR and LONG-PCR experiments in those
strains carrying ccrA2B2recombinases, revealed a unusual
fragment, of about 9 Kb, from the pls gene (cifF, primer up)
to ccrA2B2 (ccrB2, primer dw).
Figure 1c also graphically represents the alternation of
diverse clones over the 27 year time frame. Considering
the strains isolated in 1980, it can be seen that, with the
only exception of ST8, all the other clones disappeared
from hospitals. In our results, this clone, i.e. the early ST8-
MRSA-I (variable PFGE profiles), underwent a sort of evo-
lution passing from an ST8-MRSA-I (PFGE A, with 3 sub-
types) to the MDR ST247-MRSA-IA (PFGE A, with 28 sub-
types) and back again to a more susceptible clone i.e the
ST8-MRSA-IV (PFGE A, 1 sub-type) isolated in 2007. A
characteristic of the clones at the end of period A and the
beginning of period B is their multi-drug resistance, while
the majority of period B saw a reduction in the number of
these clones and a tendency towards susceptibility with
the appearance of ST8-MRSA-IV and ST22-MRSA-IV –
reflecting what was found in 1980, and indicating a possi-
ble future clinical change.
Antibiotic susceptibilities
All the 301 MRSA strains were tested for their susceptibil-
ity to all classes of antibiotics. With the only exception of
the strains isolated in 1980 that were uniformly suscepti-
ble to all non-beta lactam antibiotics, the remaining iso-
lates were multi-resistant (Table 1). Both groups – A and
B – acquired and maintained their level of resistance to
gentamicin (98.1 and 88% respectively), erythromycin
(83.1 versus 83.7%), clindamycin (85 and 75%) and cip-
rofloxacin (97 and 96.5). On the contrary, the isolates of
group A were 67% resistant to tetracycline, while only
21% of group B isolates were resistant to this drug. The
same decrease was observed for rifampin (from 66.2% to
21%) and cotrimoxazole (42 to 8.5%). The 15 MRSA
strains from 1980 had from 73.3 to 86.6% susceptibility
to all these drugs.
The measure of the temporal shift in the susceptibility
level of the anti-staphylococcal drugs, namely glycopep-
tides, linezolid, quinupristin/dalfopristin, daptomycin
and tigecycline, was observed stratifying all the MIC data
with respect to time. This distribution is shown in Figure
2. Making a comparison among MIC90 values, linezolid
was stable in periods A and B with a MIC90 value of 2 mg/
L; the same was true for quinupristin/dalfopristin (MIC90
of 1 mg/L in both periods), and for glycopeptides (2 and
4 mg/L for vancomycin and teicoplanin respectively). All
isolates of the 1980 group were uniformly more suscepti-
ble to all antibiotics, as was predictable.
Table 1: Antibiotic-resistance (%) of various antibiotics against 301 MRSA strains, compared with a sample of Italian isolates from 
1980.
Antibiotics MRSA isolated in 1980 (15) MRSA isolated in 1990–1999 (period A) 
(160)
MRSA isolated in 2000–2007 (period B) 
(141)
SRS R S R
Gentamicin 73.3 26.6 1.9 98.1 22** 88
Erythromycin 86.6 13.3 16.9 83.1 16.3 83.7
Clindamycin 86.6 13.3 15 85 35 75
Tetracycline 73.3 26.6 33.1 67 82.2° 17.8
Ciprofloxacin 80 20 3 97 3.5 96.5
Rifampin 73.3 26.6 33.7 66.3* 79 21
Cotrimoxazole 86.6 13.3 58.1*** 42 91.5 8.5
* Rifampin resistance is characteristic of CC8 (ST247 and 239)
** Including the gentamicin-susceptible clone
*** Cotrimoxazole resistance is a marker of ST 239
° The tetracycline susceptible Italian clone increased in this periodAnnals of Clinical Microbiology and Antimicrobials 2009, 8:22 http://www.ann-clinmicrob.com/content/8/1/22
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A MIC distribution evaluation demonstrated that the
most striking change was a slight but continuous shift in
vancomycin and teicoplanin MICs  over time. Table 2
shows this phenomenon in the three major clones,
ST239-MRSA-IIIA, ST247-MRSA-IA and ST228-MRSA-I,
isolated in Italy in periods A and B. While the percentage
of strains with susceptibility to vancomycin of ≤ 0.5 mg/L
was 52% in period A, this value decreased to 20.4% in
period B with a corresponding increase in the number of
strains with a MIC of 1 mg/L (44.1 versus 28.5%) and ≥ 2
mg/L (35.5% versus 19.4%). The same trend was
observed for teicoplanin.
Interestingly, this MIC creep was related to the parallel
increase in the isolation of the MDR ST228-MRSA-I clone,
in period B.
Discussion
We studied 2 collections of MRSA strains identified over a
17-year period in Italy (periods A and B). These strains are
MIC distributions of the major anti Gram-positive drugs against MRSA strains Figure 2
MIC distributions of the major anti Gram-positive drugs against MRSA strains. MIC50 and MIC90 in bold and under-
lined; MIC50 only in bold; MIC90 in grey.
MRSA isolated in 1980 (n.15) 
mg/L  0.03  0.06 0.12 0.25 0.5 1.0 2.0 4.0 8.0 16.0  
Linezolid  0 0 0 0 2  13 0 0 0 0   
Daptomycin  0 0 0 3 5  7 0 0 0 0   
Quinopristin/dalfopristin 0  0  8  7 0 0 0 0 0 0   
Tigecycline 13  0 2 0  0 0 0 0 0 0   
Vancomycin  0 0 0 0 13  2 0 0 0 0   
Teicoplanin 0  2 9 2 1 0 1 0 0 0   
                  
MRSA isolated in 1990-1999 – period A   (160) 
mg/L  0.03  0.06 0.12 0.25 0.5 1.0 2.0 4.0 8.0 16.0  
Linezolid  0 0 2 0 13  57  78 10 0  0   
Daptomycin  0 0 4 15  32 109 0 0 0 0   
Quinopristin/dalfopristin 0 2 4 34  102  18 0 0 0 0   
Tigecycline  0 0 9 59  92 0 0 0 0 0   
Vancomycin  0 0 0 1 65  61  29 4 0 0   
Teicoplanin  0 0 9 9 50  51  6  35 0 0   
                  
MRSA isolated in 2000-2007 – period B (141) 
mg/L  0.03  0.06 0.12 0.25 0.5 1.0 2.0 4.0 8.0 16.0  
Linezolid  0 0 0 1 5  47  80 8 0 0   
Daptomycin  1  4  18 34 28  39  13 4 0 0   
Quinopristin/dalfopristin  0  8  30 28 54  18 3 0 0 0   
Tigecycline 1  76 36 21 7 0 0 0 0 0   
Vancomycin  0 0 0 0 19  65  49 8 0 0   
Teicoplanin  0 0 0 0 43  34  40  24 0 0   
Table 2: Number of MRSA strains with glycopeptide MICs of ≤ 0.5, 1, and ≥ 2 mg/L in ST247-MRSA-IA, ST239-MRSA-IIIA and ST228-
MRSA-I isolated in periods A and B
ST247-MRSA-IA, ST239-MRSA-IIIA and ST228-
MRSA-I clones° 1990–1999 – period A (98)
ST247-MRSA-IA, ST239-MRSA-IIIA and ST228-
MRSA-I clones° 2000–2007 – period B (93)
MIC mg/L ≤ 0.5 1 ≥ 2 ≤ 0.5 1 ≥ 2
Vancomycin (%) 51 (52) 28 (28.5) 19 (19.4) 19 (20.4) 41 (44.1) 33 (35.5)
Teicoplanin (%) 49 (50) 25 (25.5) 22 (22.4) 20 (21.5) 30 (32.2) 43 (46.2)
° P < 0.001Annals of Clinical Microbiology and Antimicrobials 2009, 8:22 http://www.ann-clinmicrob.com/content/8/1/22
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representative of isolates collected during this time and
published in two Italian surveys [24,25]. The results were
compared with those obtained from a group of Italian
MRSA strains isolated in 1980. This report describes the
evolution of the major Italian clonal types and the evolu-
tion of their resistance to antibiotics. Due to the vast
amount of data that we had collected every year, we used
representative phenotypes of each year over the two sur-
vey periods.
The comparison of these data with those from 1980 gives
important and unique insights into long-term MRSA evo-
lution.
The presence of five major clones (ST8-MRSA-I, ST247-
MRSA-IA, ST239-MRSA-IIIA, ST228-MRSA-I and ST247-
MRSA-I/IA) was previously reported by Mato R. et al. in
1990 [7]. We demonstrate here that the prevalence of pre-
dominant clones changed over time and this change
might have significant medical consequences, since the
new clones often display different antibiotic resistance
profiles. We also demonstrate that – during this time –
there was a considerable increase in the prevalence of
MDR clones, with the Italian one becoming predominant
in our country. Furthermore, we demonstrate that the iso-
lation of MRSA strains with a vancomycin MIC ≥ 2 mg/l is
more frequent in the nosocomial-acquired strains of the B
period, and that this shift is also present for teicoplanin.
Epidemiological evolution of MRSA clones
All major circulating clones in Italy belonged to the 4
most common genetic background types (ST8, ST247,
ST239, and ST228) and they have also been reported, for
a long time, as main isolates from studies of HA-MRSA all
around the world. Among these clones, ST228 was preva-
lently found in Europe and was first isolated in 1995 in
South-Germany, Slovenia, Austria, and Italy [33,34]. This
clone still represents, in our country, the most common
HA-MRSA clone, it is not related to any other national
clones, and its genetic background closely correlates with
those of several S.aureus  including MSSA, MRSA, and
VISA, all belonging to the clonal complex 5 (CC5), con-
firming the role of horizontal transfer of mecA among dif-
ferent ancestral lineages, originating from a well adapted
MSSA strain. In our country, this clone doubled its preva-
lence during the study period, accounting for more than
half of the MRSA strains isolated in period B.
The evolutionary history of clones belonging to CC8 (ST8-
MRSA-I, ST247-MRSA-IA, ST247-MRSA-I and IA, and ST8-
MRSA-IV) is more complex. The acquisition of diverse SCC-
mec elements and/or other genetic elements, likely occurred
in several occasions in this genetic background [8]. The few
CC8 1980 clones in our study, shared SCCmec cassettes
similar to SCCmec type I, probably their precursors.
During period A, we documented the evolution of the
ST8-MRSA-I towards a more resistant phenotype, acquir-
ing and integrating different genetic elements, in particu-
lar the plasmid pUB110  (carrying kanamycin and
neomycin resistance genes) into the SCCmec region, giv-
ing the original type I cassette a more complex organiza-
tion (SCCmec  IA), and two copies of Tn554  (carrying
erythromycin and spectinomycin resistance determi-
nants) integrated in the genome. This clone, although
being more resistant to antibiotics, maintained the same
PFGE profile A (with diverse sub-types), and belongs to
ST247, a single locus variant of ST8.
ST239-MRSA-IIIA had a short history in Italy, probably
because it had come from other countries [35]. This clone
is poorly represented in both periods A and B.
Period A was also characterized by the emergence of a
local clone (Rome clone) possessing the same ST247 of
the more diffused Iberian one, but with two different
important characteristics: i) a different PFGE profile; ii) a
predisposition to low level susceptibility to vancomycin,
producing an hVISA phenotype [32]. The replacement of
ST247 in recent years (period B) in our country has also
involved this clone, which is now scarcely represented.
The decline, during period B, of ST247-MRSA-IA is docu-
mented in this study. Recent reports have shown that this
clone was replaced by other pandemic clones [23,35-38].
The replacement of ST247-MRSA-IA might suggest that it
had lost its epidemic potential during the last decade.
Also during period B, in which ST228-MRSA-I consoli-
dated its presence and ST247 decreased, there was the re-
appearance of ST8, carrying a different SCCmec type IV,
that resembles the ancient one, being less resistant to anti-
biotics. In fact, the recent appearance of this clone is of
interest, because it maintained a profile of antibiotic-sus-
ceptibility.
Finally, in the last two years of period B, different MRSA
strains such as the gentamicin-susceptible ST22-MRSA-IV
strain, appeared in different wards in some Italian hospi-
tals. This appearance was accompanied, in the commu-
nity, by the isolation of hyper-virulent, pvl-positive MRSA
strains, belonging to ST8-MRSA-IV, ST30-MRSA-IV and
ST88-MRSA-V, which we documented in Italy [15,39].
Evolution of antibiotic-resistance
The multi-drug resistant phenotype is a particular charac-
teristic of the methicillin-resistant S.aureus strains, almost
related to the global presence and spread of MDR clones
[14,40]. The homogeneous insusceptibility to all beta-
lactams, characteristic of methicillin-resistant strains,
together with the continuous accumulation and organiza-Annals of Clinical Microbiology and Antimicrobials 2009, 8:22 http://www.ann-clinmicrob.com/content/8/1/22
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tion of many resistance genes, has made this species par-
ticularly difficult to treat. This diffused antibiotic-
resistance is true for many classes of antibiotics such as
aminoglycosides, macrolides, lincosamides, and fluoro-
quinolones, which, as demonstrated in this paper on con-
temporary isolates, appeared to maintain a low level of
activity against MRSA. A notable exception seems to be the
increased level of susceptibility to gentamicin found in
MRSA isolated in period B, mainly due to the appearance,
in our hospitals, of a gentamicin-susceptible clone,
belonging to ST22.
The percentage of resistance to tetracycline, rifampin and
cotrimoxazole, increased in period A, but decreased in
period B: in this case the different antibiotic susceptibility
patterns are linked to the epidemiologic change and
replacement of clones with specific markers of resistance.
In our study, the decrease in resistance to these three drugs
is due to the replacement of the rifampin resistant ST247-
MRSA-IA, ST239-MRSA-IIIA and ST247-MRSA-I/IA with
the tetracycline susceptible ST228-MRSA-I [7].
The trend of susceptibility to the most used anti-MRSA
drugs, as evaluated in our study, demonstrated that no
resistance to vancomycin, teicoplanin, daptomycin, line-
zolid and quinupristin/dalfopristin was observed in the
time frame of the study. Among these drugs, only dapto-
mycin has recently been approved and marketed, explain-
ing the substantial stability of the MIC50 and MIC90 over
time. On the contrary, the evaluation of the MICs of the
population of MRSA demonstrated something compara-
ble to that observed for other classes of drugs: the strains
isolated in period B, in which MDR clones were replaced
by others with different resistance make-ups, show a dis-
tribution toward the lowest MIC concentrations. The
same can be observed for quinupristin/dalfopristin.
Although reports of linezolid resistance in S.aureus  are
increasing [41,42] data on MIC creep are infrequent
(Golan Y et al, Abstract from the 46th ICAAC, San Fran-
cisco CA 2006; Abs C2-1157 p. 127). In our study,
changes in distribution of susceptibility for linezolid are
comparable in the two periods, demonstrating a one dilu-
tion increase in MIC only if compared with the suscepti-
bility demonstrated during 1980. This creep towards
higher levels of MICs is clear if glycopeptides are consid-
ered and mostly related to the increased isolation of the
MDR ST228-MRSA-I clone in period B. This slight but
continuous increase in the level of susceptibility of vanco-
mycin was reported by many studies all around the world
[14,43,44], many of them demonstrating a strict correla-
tion between increased MIC values and therapeutic failure
in infections sustained by MRSA [43,45,46]. The MIC
creep phenomenon has produced conflicting results most
likely due to the MIC statistics used [47,48]. Reports from
large multicenter studies have not demonstrated changes
in vancomycin susceptibilities over time [44]. However,
these types of studies are not designed to detect subtle
changes in MICs. As reported by other investigators, we
demonstrate a statistically significant increase in MRSA
vancomycin and teicoplanin MICs over time. The magni-
tude of this increase was similar in both drugs, but the
largest increase was observed for vancomycin, in which
strains showing a MIC > 1 mg/L increased from 47 to
78%.
In conclusion, we document here the alternation of multi-
drug resistant MRSA clones in the 1990–2007 period,
with the establishment of ST228-MRSA-I in our country,
with respect to the clones present in 1980. The increase of
the glycopeptide MIC levels, reflecting a worldwide trend,
was also documented, due to the massive use of these
drugs in clinical practice. We detected ST1, ST8, ST15, and
ST30 in the 1980 isolates; thus we hypothesize their re-
appearance as backgrounds for the current CA-MRSA
clones, due to mechanisms as yet unknown.
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